Evidence map›Paper›PMID 30073432›Full record

Observational studyEuropean journal of clinical pharmacology2018

Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?

Saoussen Chouchene, Rym Dabboubi, Haythem Raddaoui, Hela Abroug, Khaldoun Ben Hamda, Sondess Hadj Fredj, Fatma Abderrazak, Mayssa Gaaloul, Marwa Rezek, Fadoua Neffeti and 9 more

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03373552 (Determination of Genetic Polymorphisms Contributing to the Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03373552 active not recruitingnot on this map

Determination of Genetic Polymorphisms Contributing to the Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response

Typeobservational_patient_registrySponsorHôpital Universitaire Fattouma BourguibaRan2015 to 2029Enrolled250ConditionsCoronary DiseaseArmsPlatelet function assay
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Beyond CYP2C19: inflammation and angiogenesis gene variants drive clopidogrel resistance in CAD patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  3. The influence of P2YFuture cardiology · 2024
    Article
  4. Analysis ofFrontiers in cardiovascular medicine · 2023
    Article
  5. Article
  6. Article
  7. ShouldPharmacogenomics and personalized medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Saoussen ChoucheneHematology Department, Fattouma Bourguiba University Hospital, TN 5000, Monastir, Tunisia. saoussen_chouchene@yahoo.fr.ORCID http://orcid.org/0000-0001-7663-5158
Rym DabboubiBiochemistry and Molecular Biology Laboratory (LR00SP03), Children's Hospital Bechir Hamza, 1006, Tunis, Tunisia.
Haythem RaddaouiCardiology Department, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Hela AbrougEpidemiology and Preventive Medicine Department, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Khaldoun Ben HamdaCardiology Department, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Sondess Hadj FredjBiochemistry and Molecular Biology Laboratory (LR00SP03), Children's Hospital Bechir Hamza, 1006, Tunis, Tunisia.
Fatma AbderrazakHematology Department, Fattouma Bourguiba University Hospital, TN 5000, Monastir, Tunisia.
Mayssa GaaloulHematology Department, Fattouma Bourguiba University Hospital, TN 5000, Monastir, Tunisia.
Marwa RezekHematology Department, Fattouma Bourguiba University Hospital, TN 5000, Monastir, Tunisia.
Fadoua NeffetiBiochemistry Department, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Ilhem HellaraBiochemistry Department, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Mouna SassiBiology Department, Maternity and Neonatal Medicine Center, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Linda KhefachaBiology Department, Maternity and Neonatal Medicine Center, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Asma SrihaEpidemiology and Preventive Medicine Department, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Semir NouiraResearch Laboratory (LR12SP18), University of Monastir, 5000, Monastir, Tunisia.
Mohamed Fadhel NajjarBiochemistry Department, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Faouzi MaatoukCardiology Department, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia.
Taieb MessaoudBiochemistry and Molecular Biology Laboratory (LR00SP03), Children's Hospital Bechir Hamza, 1006, Tunis, Tunisia.
Mohsen HassineHematology Department, Fattouma Bourguiba University Hospital, TN 5000, Monastir, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClopidogrel non-responsiveness is multifactorial; several genetic and non-genetic factors may contribute to impaired platelet inhibition. The goal of this study is to determine the effect of the cytochrome P450 CYP2C19*2 polymorphism on the platelet response to clopidogrel in patients with and without diabetes mellitus (DM).

methodsWe conducted an observational study in patients with coronary artery disease and consequent exposure to clopidogrel therapy (75 mg/day for at least 7 consecutive days). We have analyzed two groups of patients: group I (DM patients) and group II (non-diabetes mellitus patients). Platelet reactivity was assessed by the VerifyNow P2Y12 assay and high on clopidogrel platelet reactivity (HPR) was defined as P2Y12 reaction units (PRU) ≥ 208. Genotyping for CYP2C19*2 polymorphism was performed by PCR-RFLP.

resultsWe have included 150 subjects (76 DM and 74 non-diabetes mellitus patients). The carriage of CYP2C19*2 allele, in DM patients, was significantly associated to HPR (odds ratio (OR) 4.437, 95% confidence interval (CI) 1.134 to 17.359; p = 0.032). Furthermore, 8.4% of the variability in percent inhibition by clopidogrel could be attributed to CYP2C19*2 carrier status. However, in non-diabetes mellitus patients, there was no significant difference in platelet response to clopidogrel according to the presence or absence of CYP2C19*2 allele carriage (OR 1.260, 95% CI 0.288 to 5.522; p = 0.759).

conclusionsOur study suggests that the carriage of CYP2C19*2 polymorphism, in DM patients, might be a potential predictor of persisting HPR in these high-risk individuals.

trial registrationClinical Trials.gov NCT03373552 (Registered 13 December 2017).

Indexed as

AdultAgedBlood PlateletsClopidogrelCoronary Artery DiseaseCross-Sectional StudiesCytochrome P-450 CYP2C19Diabetes MellitusDiabetic AngiopathiesFemaleGenotypeHeterozygoteHumansMaleMiddle AgedPlatelet Aggregation InhibitorsClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsClopidogrelCoronary artery diseaseCytochrome P-450 CYP2C19Diabetes mellitus

Identifiers

PMID30073432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.